CLIN CANCER RES:前列腺癌RET信号

2017-08-29 MedSci MedSci原创

神经浸润的大直径前列腺癌预后较差。GDNF及其共受体GFRα1结合RET,激活下游的癌前信号。GDNF及GFRα1均由神经分泌。CLIN CANCER RES近期发表了一篇文章, 研究前列腺癌中RET信号的作用。

神经浸润的大直径前列腺癌预后较差。GDNF及其共受体GFRα1结合RET,激活下游的癌前信号。GDNF及GFRα1均由神经分泌。CLIN CANCER RES近期发表了一篇文章, 研究前列腺癌中RET信号的作用。

作者检测了RET,GDNF以及GFRα1的表达。评估RET信号对增殖,侵袭,软琼脂集落形成,神经周围浸润及体内肿瘤生长的影响。利用Western blot分析RET下游分子信号。研究结果表明,所有前列腺癌细胞系RET均有表达。GFRα1仅表达与22Rv1细胞,该细胞为唯一的对外源性GDNF有反应的细胞系。所有细胞系均对GDNF加GFRα1有反应。含有神经分泌的GFRα1的条件培养基可以促进转化相关亚型,这种作用可以被抗GFRα1抗体阻断。抗GFRα1抗体以及RET敲除可以抑制神经周围浸润。在体内实验中,RET敲除后抑制肿瘤生长。根据条件不同,RET信号可以激活ERK或AKT信号,p70S6酶磷酸化显着升高。p70S6酶敲除可以显着降低RET介导的转化亚型。RET在约18%的腺癌及所有3个小细胞癌中均表达。

文章最后认为,RET促进亚型相关转化,包括p70S6酶活化介导的前列腺癌神经浸润。神经分泌的GFRα1是RET信号的限制因素,为RET信号出现创造神经周围环境。

原始出处:
Kechen Ban,Shu Feng,et al.RET Signaling in Prostate Cancer.CLIN CANCER RES.August 2017 doi:10.1158/1078-0432.CCR-17-0528

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1913841, encodeId=7ba319138415b, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Sep 03 15:33:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238785, encodeId=6da5238e8574, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 30 22:58:51 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238408, encodeId=4511238408f1, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Aug 29 19:58:40 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238380, encodeId=baee238380ba, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Aug 29 17:34:08 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-09-03 ysjykql
  2. [GetPortalCommentsPageByObjectIdResponse(id=1913841, encodeId=7ba319138415b, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Sep 03 15:33:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238785, encodeId=6da5238e8574, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 30 22:58:51 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238408, encodeId=4511238408f1, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Aug 29 19:58:40 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238380, encodeId=baee238380ba, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Aug 29 17:34:08 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-30 luominglian113

    学习了.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1913841, encodeId=7ba319138415b, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Sep 03 15:33:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238785, encodeId=6da5238e8574, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 30 22:58:51 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238408, encodeId=4511238408f1, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Aug 29 19:58:40 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238380, encodeId=baee238380ba, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Aug 29 17:34:08 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-29 131****1460

    学习了受益匪浅.

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1913841, encodeId=7ba319138415b, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Sep 03 15:33:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238785, encodeId=6da5238e8574, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 30 22:58:51 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238408, encodeId=4511238408f1, content=学习了受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Aug 29 19:58:40 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238380, encodeId=baee238380ba, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Aug 29 17:34:08 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-29 1ddf0692m34(暂无匿称)

    学习了.好文章

    0

相关资讯

Eur Urol:放疗后怀疑前列腺癌复发,穿刺部位如何选?

对初次放疗没有反应的前列腺癌男性患者来说,精确了解肿瘤复发或持续的部位有利于认识治疗失败的原因。

Eur Urol:不同初始治疗方案对局限性前列腺癌患者的长期心理和生活质量影响。

长期的心理健康和生活质量是低风险前列腺癌患者在决定是否接受积极治疗时重要的考虑因素。

Ann Oncol:apalutamide治疗去势耐受前列腺癌时,雄激素受体基因突变较少

背景:雄激素受体(AR)的配体结合域(LBD)的基因突变,如F877l和T878A,已被证实能抑制下一代AR定向疗法。ARN-509-001是一项I/II期研究,该研究主要评估在去势耐受前列腺癌(castration-resistant prostate cancer,CRPC)中apalutamide的活性。apalutamide是一种竞争性雄激素受体抑制剂。本研究中,研究人员评估了apalut

Sci Rep: 活性氧在前列腺癌中可控制基质细胞和癌细胞中MMP-3的表达

关于细胞外基质(ECMs)间接控制的研究主要集中在恶性肿瘤细胞的作用,而在癌症发展期间基质细胞的作用上关注较少。因此,最近有研究人员通过利用来自共培养细胞模型和临床病人样本的正常和前列腺癌基质细胞(CAFs),阐释了尽管CAFs可以促进前列腺癌的生长,基质金属蛋白酶-3(MMP-3)在CAFs中表达量较低,而在前列腺癌细胞中表达量提高。更进一步的是,研究人员发现过氧化氢通过不同的调控机制,为MMP

盘点:近期前列腺癌研究进展一览

前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常我们所说的前列腺癌就是指前列腺腺癌。梅斯医学小编整理了近期前列腺癌的研究进展,与大家一起分享学习!【1】Nat Genet:原发性前列腺癌中,TMPRSS2-ERG调控转录

Eur Urol:向精密泌尿系肿瘤学方向迈进,一种新型的AR拮抗剂

Darolutamide(ODM-201)是一种新型的雄激素受体(AR)拮抗剂,其化学结构与目前批准的AR拮抗剂有明显差异,主要针对野生型和突变型的配体结合域突变体抑制AR核转位。